Belite Bio’s (BLTE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research note published on Thursday morning, Benzinga reports. Several other research analysts have also recently weighed in on the company. Benchmark reissued a buy rating and issued a $57.00 price objective on shares of Belite Bio in a […]

Leave a Reply

Your email address will not be published.

Previous post Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) Receives Average Rating of “Hold” from Analysts
Next post Pols & Politics: As time runs out, meeting state budget deadline only a ‘point of pride’ for one top Democrat